Evolus Eyes 2027 Sculpt Launch as Filler Portfolio Expands and Revenue Grows

Evolus (NASDAQ:EOLS) executives said the company expects its expanding lineup of injectable aesthetics products to support growth as it prepares for the anticipated launch of Evolysse Sculpt in 2027.

At a company event, CEO and President David Moatazedi said Evolus has diversified beyond its flagship Jeuveau wrinkle treatment by introducing hyaluronic acid fillers in the U.S. and Europe. The company expects international operations to account for 10% of revenue this year.

CFO Tatjana Mitchell said revenue grew 14% year over year through the third quarter while operating expenses declined slightly. Evolus reaffirmed its full-year revenue guidance of $330 million to $337 million, representing growth of 11% to 13%, and its forecast for adjusted EBITDA in the low- to mid-single digits as a percentage of revenue.

Market demand and product expansion

Moatazedi characterized the aesthetics market as healthy, estimating that the toxin market grew in the upper single digits in the third quarter. He said the filler market, which had faced weaker consumer sentiment and slowing demand, has stabilized and is roughly flat to slightly growing this year.

Consumers seeking a more natural appearance are using less filler per treatment than during the post-COVID boom, Moatazedi said. He estimated that patient volume in the filler market could be growing in the mid- to high-single digits even as unit volumes remain roughly flat.

He also said clinics are seeing patients who use GLP-1 drugs express concern about facial volume loss. Evolus has used the mention of GLP-1s in the Evolysse label in advertising developed with clinics, he said.

Moatazedi said more than 3,500 facilities have purchased Evolysse in the five quarters since launch, with reorder rates moving closer to Jeuveau levels. Evolysse is approaching a mid-single-digit market share, he said.

Sculpt launch and clinic incentives

Evolus expects to launch Evolysse Sculpt in the first quarter of 2027, subject to approval, followed by a lip product in 2028. Moatazedi said Sculpt, a mid-face product, could help clinics shift more of their filler business to Evolus. Mitchell said the product addresses 40% to 50% of the market.

Chief Medical Officer Rui Avelar said Sculpt is designed to provide more projection than the company’s existing fillers. He said Evolus expects its Form product to continue growing in other uses rather than be displaced by Sculpt.

The company also is using a portfolio growth rebate to encourage clinics to purchase more products. Moatazedi said accounts that participated in the program during the first half of the year were the fastest-growing part of the business. Mitchell said Evolus is repeating the six-month program in the second half and testing an additional offering for another group of accounts.

Mitchell said Evolus has posted four quarters of adjusted EBITDA profitability, demonstrating its ability to add products without rebuilding its commercial platform. The company will invest in the Sculpt launch but can use existing sales, marketing, education and technology capabilities, she said.

Pipeline and longer-term outlook

Avelar discussed Profhilo, a skin-quality product in development that is designed to hydrate skin, as well as a hair-rejuvenation program using known small molecules. Evolus is working on formulations intended to release over three to four months and expects human data around the end of 2028 before deciding whether to enter a full development program, he said.

Evolus also remains interested in adding a biostimulator product, Avelar said. Such products stimulate collagen, and the company is looking for the right asset and deal structure.

Discussing the company’s 2028 outlook, Mitchell said market conditions have aligned with its assumptions. She identified the Sculpt and lip-product launches as key components and said Evolus expects approval for Estyme in Canada, Australia and New Zealand by 2028. She described 2027 as a transition toward selling the full toxin and filler portfolio across the company’s geographies.

About Evolus (NASDAQ:EOLS)

Evolus, Inc. is a medical aesthetics company focused on developing and commercializing treatments for cosmetic procedures. The company’s portfolio includes injectable products used by healthcare professionals to address facial lines and wrinkles and to enhance facial appearance. Its flagship product, Jeuveau (prabotulinumtoxinA-xvfs), is a prescription botulinum toxin treatment for moderate to severe frown lines between the eyebrows in adults. Evolus also markets Evolysse, a line of hyaluronic acid dermal fillers designed for facial aesthetic treatments.